Preserving hearing is our mission
Oricula Therapeutics, LLC, is working to develop the first medication to be approved to prevent drug-induced hearing loss. Our first product ORC-13661, will prevent the hearing loss that is a frequent side effect of the administration of the aminoglycosides, an important class of antibiotics,. Reducing or eliminating this hearing loss would allow broader and more effective worldwide use of these important antibiotics for the treatment of life-threatening bacterial infections, such as pneumonia, endocarditis, neonatal septicemia and multi-drug resistant tuberculosis. The FDA has allowed our Investigational New Drug (IND) filing for this product to move forward to early human testing.